Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001931531 | SCV002201245 | uncertain significance | Hyperphosphatasia with intellectual disability syndrome 2 | 2021-08-11 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine with valine at codon 862 of the PIGO protein (p.Leu862Val). The leucine residue is moderately conserved and there is a small physicochemical difference between leucine and valine. This variant is present in population databases (rs377645902, ExAC 0.02%). This variant has not been reported in the literature in individuals affected with PIGO-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002560682 | SCV003586654 | uncertain significance | Inborn genetic diseases | 2021-10-27 | criteria provided, single submitter | clinical testing | The c.2584C>G (p.L862V) alteration is located in exon 7 (coding exon 6) of the PIGO gene. This alteration results from a C to G substitution at nucleotide position 2584, causing the leucine (L) at amino acid position 862 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |